Are you curious to know how you can excel in US market access strategy? We have extensive experience with high profile dynamics in the US, this ranges from thorough price analyses that span early phase ‘gut checks’ to launch optimization and beyond.

Questions Our Clients Ask

  • How restrictive will the payer prior authorization be for our product?
  • What is our value-based price?
  • How will access change for the follow-on indication?
  • What will payer management look like in disease state X in the next five years?
  • What are the specific access hurdles the practice is experiencing with our product

Specialist Therapeutic Areas

Oncology, MS, Respiratory Immunology (RA/PsA/CD/UC), Orphan Disease, Haemophilia, Cardiovascular, etc.

Specialized Markets

The CBP Difference

  • We have vast experience supporting the P&MA launch strategy of high-profile brands and can help clients solve highly nuanced problems (i.e. HUB financial assistance program, HRU model.)
  • We have extensive experience with high profile dynamics such as: gene therapy, alternative payment models, NGS testing, portfolio contracting, etc.